Archives

  • 2026-07
  • 2026-06
  • 2026-05
  • 2026-04
  • 2026-03
  • 2026-02
  • 2026-01
  • 2025-12
  • 2025-11
  • 2025-10

    • GLP-1 (9-36) amide: Precision Antagonist for GLP-1 Recept...

    2026-03-12

    GLP-1 (9-36) amide: Precision Antagonist for GLP-1 Receptor Pathway Studies

    Executive Summary: GLP-1 (9-36) amide is a synthetic peptide antagonist for the human GLP-1 receptor, widely used for dissecting incretin hormone signaling (Chepurny et al., 2019). The compound is supplied as a white lyophilized solid (MW 3089.44 Da) by APExBIO, with 100% purity confirmed by HPLC and mass spectrometry (APExBIO product page). GLP-1 (9-36) amide is insoluble in water and standard organic solvents, requiring specific handling protocols. Its antagonist activity enables precise mapping of GLP-1 receptor contributions to metabolic regulation, including type 2 diabetes mechanisms (internal review). The peptide's instability in solution mandates rapid post-reconstitution use for experimental fidelity.

    Biological Rationale

    GLP-1 (9-36) amide is derived from the endogenous GLP-1 peptide, an incretin hormone secreted by intestinal L-cells in response to nutrient intake (Chepurny et al., 2019). GLP-1 modulates glucose homeostasis by stimulating insulin secretion and suppressing glucagon release. Its effects are mediated through binding to the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed in pancreatic beta cells, brainstem, and peripheral tissues. Understanding receptor-specific signaling is essential for metabolic regulation and type 2 diabetes research. Peptide antagonists like GLP-1 (9-36) amide allow selective inhibition of GLP-1R, enabling differentiation of canonical and noncanonical receptor pathways. This specificity is crucial for mapping cross-reactivity with other GPCRs (e.g., glucagon or GIP receptors) and for developing targeted therapies (advanced insights).

    Mechanism of Action of GLP-1 (9-36) amide

    GLP-1 (9-36) amide acts as a competitive orthosteric antagonist at the human GLP-1 receptor (Chepurny et al., 2019). It binds to the same extracellular domain as endogenous GLP-1, blocking receptor activation and downstream cAMP signaling. In high-throughput FRET cAMP assays, GLP-1 (9-36) amide inhibits GLP-1-induced cAMP accumulation in INS-1 832/13 beta cells. This blockade does not extend to glucagon or GIP-mediated pathways at physiological concentrations, confirming its selectivity under defined conditions (benchmark analysis). The peptide's structure (C140H214N36O43) and sequence facilitate receptor binding but lack intrinsic agonist activity. When used in combination with GLP-1 or other receptor ligands, GLP-1 (9-36) amide allows precise dissection of receptor-specific signaling events.

    Evidence & Benchmarks

    • GLP-1 (9-36) amide inhibits GLP-1-induced cAMP signaling in beta cell FRET assays, with IC50 values in the low micromolar range at 37°C, pH 7.4 (Chepurny et al., DOI).
    • The compound displays no significant antagonism toward glucagon or GIP signaling at the GLP-1R under standard assay conditions (DOI).
    • Batch purity is consistently confirmed ≥99% by HPLC and mass spectrometry in APExBIO quality control reports (product specification).
    • Stability testing indicates GLP-1 (9-36) amide remains active for at least 12 months when stored desiccated at -20°C in lyophilized form (product data).
    • Cross-laboratory reproducibility in GLP-1 receptor signaling studies is demonstrated in multiple peer-reviewed reports using this peptide as a reference standard (practical guide).

    Applications, Limits & Misconceptions

    GLP-1 (9-36) amide is used in metabolic regulation, type 2 diabetes research, and GLP-1 receptor signaling studies. It allows for:

    • Dissecting GLP-1-specific pathways in cell-based and in vivo models.
    • Validating the specificity of GLP-1R-targeted drug candidates.
    • Clarifying receptor cross-talk and off-target effects within the incretin system (Chepurny et al., 2019).

    For more advanced experimental differentiation, see GLP-1 (9-36) amide: Advanced Insights into GLP-1 Receptor..., which details hybrid and triagonist peptide approaches. Our present article clarifies the antagonist's unique selectivity profile and practical handling, extending previous molecular analyses.

    Common Pitfalls or Misconceptions

    • Non-specific inhibition: GLP-1 (9-36) amide does not antagonize glucagon or GIP receptors at standard concentrations (DOI).
    • Solubility: The peptide is insoluble in DMSO, ethanol, and water; attempts at dissolution in these solvents yield poor recovery.
    • Storage: Dissolved peptide rapidly degrades at room temperature—lyophilized storage at -20°C is mandatory for stability.
    • Functional readout: Absence of cAMP signaling does not confirm complete receptor blockade; use appropriate controls.
    • Species specificity: Data herein pertains to human GLP-1R; cross-species differences may exist.

    Workflow Integration & Parameters

    GLP-1 (9-36) amide is supplied by APExBIO (SKU B5404) in lyophilized format, with accompanying Certificate of Analysis and Material Safety Data Sheet (product page). For best results:

    • Store lyophilized peptide desiccated at -20°C; avoid repeated freeze-thaw cycles.
    • Reconstitute immediately before use using a compatible buffer system, such as 0.1% TFA in acetonitrile-water mixtures, as per protocol (workflow guide).
    • Use within 1–2 hours of dissolution to minimize degradation.
    • For cell-based assays, titrate antagonist concentrations (0.1–10 μM) and include parallel GLP-1 agonist controls.
    • Shipping is performed on blue ice for small molecules or dry ice for peptides/nucleotides.

    This article extends the practical integration advice found in GLP-1 (9-36) amide (SKU B5404): Practical Solutions... by providing updated stability and purity benchmarks.

    Conclusion & Outlook

    GLP-1 (9-36) amide is the benchmark GLP-1 receptor antagonist peptide for dissecting incretin signaling and metabolic regulation. Its high purity, defined mechanism, and precise handling requirements enable reproducible research in type 2 diabetes and beyond. As new hybrid and triagonist peptides emerge (Chepurny et al., 2019), GLP-1 (9-36) amide will remain vital for control experiments and pathway validation. For technical details, see the GLP-1 (9-36) amide product page from APExBIO. For advanced mechanistic insight, refer to GLP-1 (9-36) Amide: Unraveling Noncanonical GLP-1 Receptor..., which explores noncanonical signaling not covered here.